The Searle CompanyT O L E A D I N I M P R O V I N G T H E Q U A L I T Y O F H U M A N L I F E

CORPORATE BRIEFING SESSION

2

Brief history of IBLPA R T N E R S H I P, I N T E G R I T Y, PA S S I O N & E X C E L L E N C E

• The Group began its operations several generations ago with the inception of a distribution house. In 1887 it became distributors for W.D. & H.O. Wills cigarettes for all the pre-partition Indian sub-continent including Burma and Ceylon. As the business progressed over the next few decades, the Group established offices in several major cities, including Karachi and Lahore

• In 1993 IBL, bought the local operations of G.D. Searle, an American pharmaceutical manufacturer and successfully manages that operations to date.

• Other new companies were established to manage IBL’s businesses according to product lines and industries in a better and more organized way, and thus, IBL became the IBL Group.

3

O U R FA M I LY A N D T H E I R A F F I L I AT E S

IBL Business Operations

IBL

Brief history of SearlePA R T N E R S H I P, I N T E G R I T Y, PA S S I O N & E X C E L L E N C E

• Originally founded in US in 1888 by Gideon D. Searle.

• Incorporated in Pakistan as a Private Limited Company in 1965 as a subsidiary of G.D. Searle & Co., USA.

4

Our FootprintT O U C H I N G L I F E O F M I L L I O N S B Y B R I N G I N G E X C E L L E N C E I N C O M M E R C I A L O P E R AT I O N S

A Passionate Team of

Medical Sales Professionals Serving the Nation

1,900

4 Brands

Billion Rupee Club

No.

1i. Cardiovascular ii. Pain Management iii. Gynae and Obsiv. Cough Suppressant

Largest Pharmaceutical Company

2ND

In terms of Product Consumptions(Unit)

1BillionPlus

500MnPlus

7 Brands

500 Million Plus Club

18%

Growing with Double Digit on 13 yr horizon

CAGR 13 YR

>650,000Everyday

Prescriptions are prescribed by Doctors

No.

2i. Pulmonology ii. Neurology and Pediatrics

No.

3i. Anti-Infectives

Our PromiseC O M M I T M E N T T O E X C E L L E N C E

6

01

02

03

04

Searle was ranked as the most outstanding company in Pakistan as per Asiamoney’s Outstanding Companies Poll, 2018.

Searle since 2018, has been a part of Forbes Asia’s Best Under A Billion rankings for four consecutive years.

Searle was included in Financial Times Stock Exchange Index, a London based index, for international investors to track their funds in 2017.

As per MSCI, Searle was top ranked listed entity of Pakistan with the highest performance growth of 52% in share prices.

Our Product PortfolioM A R K E T I N G A U T H O R I Z AT I O N

15Biotech

Registration

288Global

Registration

25Enlistments

6Drug

Manufacturing License

470Local

Registration

18Medical Device

Registration

Our BrandsL E A D I N G B R A N D S I N T H E I R T H E R A P E U T I C A R E A

8

• HydryllinCough

• NuberolMuscle

Relaxant

• PeditralORS

• Extor, Spiromide, Byscard

Cardiovascular

• Tramal, RotecAnalgesic

• Gravinate, Lomotil, Selanz

Gastrointestinal

• Venofer, FerinjectIron Plain

• Tainem, InvanzAntibiotics

• DecaderonCorticosteroid

• SustecNitrites & Nitrates

• SinemetAnti Parkinson

Our PartnersT R U S T O F O U R A F F I L I AT O R S

9

Existing Market - 15

Future Market - 7

Our PresenceO U R B O N D W I T H T H E G L O B A L V I L L A G E

Afghanistan

Sri Lanka

Myanmar

Laos

Vietnam

Cambodia

Senegal

Ivory Coast

Ghana

Nigeria

Cameroon

Sudan

Ethiopia

Yemen

Tanzania

Kenya

Uganda

Mauritius

Maldives

PhilippinesRwanda

Oman

Guatemala

Our FacilitiesS TAT E - O F - T H E - A R T FA C I L I T I E S

• Karachi Plant 1 (GD Searle)

• Karachi Plant 2 (MSD)

• Lahore Plant 1; Lahore Plant 2

Searle Company Limited

• Nextar Plant Port QasimSearle Biosciences

• Lahore IV FacilitySearle Laboratories

• Consumer FacilitySearle Consumer

6 Manufacturing Facilities

Producing

>250MillionUnits Annually

CERTIFICATIONS

Our R&D CENTER

TSCL has established a state-of-

the-art Research & Development

Centre at ICCBS Technology Park

with first of its kind technology

incubator in Pakistan.

I N T E R N AT I O N A L C E N T E R F O R C H E M I C A L A N D B I O L O G I C A L S C I E N C E S ( I C C B S ) , U N I V E R S I T Y O F K A R A C H I

340,499,281

208,042,622

192,321,726

160,995,167

126,603,463

125,350,831

123,038,392

91,256,969

85,934,218

84,158,023

GSK

Searle

Abbot

Sami

MartinDow

GSK Con

Getz

Atco

Barret

Bosch

Growth %

-4.23%

17.95%

0.53%

7.60%

7.25%

8.05%

2.88%

3.51%

-0.46%

-1.48%

11.52%

7.04%

6.51%

5.45%

4.28%

4.24%

4.16%

3.09%

2.91%

2.85%

Industry RankingsSEARLE IS RANKED NUMBER 2ND IN TERMS OF VOLUME AND RANKEND 4TH IN TERMS OF VALUE

2020 – VOLUME IMS MAT SEPTEMBER

33,435,849,263

30,474,276,785

29,749,584,139

28,084,578,651

26,775,274,409

21,009,215,334

16,016,737,326

15,197,233,436

14,007,419,618

13,572,637,277

GSK

Getz

Abbott

Searle

Sami

Martin Dow

GSK Con

High-Q

Hilton

Bosch

Growth %

7.20%

12.05%

13.48%

17.31%

16.63%

16.95%

26.66%

3.95%

3.05%

9.69%

2020 – VALUE IMS MAT SEPTEMBER

6.88%

6.28%

6.13%

5.79%

5.52%

4.33%

3.30%

3.13%

2.89%

2.80%

Market Share Market Share

10.31% 0.94%

Our VolumeSEARLE JUMPED FROM BEING AT NUMBER 8TH IN 2008 TO NUMBER 2ND IN 2020 IN THE IMS RANKING WITH REFERENCE TO REVENUE IN TERMS OF UNITS SOLD

208,042

198,157

176,602

161,338

115,000

107,000

100,000

84,000

76,000

72,000

80,000

71,000

56,000

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

Rank

3rd

2nd

4th4th

5th

6th

6th

6th

7th

7th

8th

Searle has a large and sustainable customer base because of more focus on the treatment of chronic diseases.

3rd

3rd

2nd

Val

ue

in T

ho

usa

nd

s

28,084

26,776

22,843

17,163

12,811

11,790

9,809

8,078

6,849

5,696

5,000

4,300

3,300

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

Rank

6th

5th

6th

7th

8th

8th

8th

8th

9th

11th

Our PositionSEARLE JUMPED FROM BEING AT NUMBER 11TH IN 2008 TO NUMBER 4TH IN 2020 IN THE IMS RANKING WITH REFERENCE TO REVENUE IN TERMS OF VALUE

5th

4th

4th

Val

ue

in M

illio

ns

Our RevenueT H E R E V E N U E I N S E A R L E I N C R E A S E D R A P I D LY D U R I N G T H E L A S T 2 0 Y E A R S

2000 20202008

Management change

The revenue of the company grown from 2.7 billion in 2008 to 20.4 billion in 2020, representing an average growth rate of 18.31% per annum

The revenue in 2000 was 1.3 billion and were 2.0 billion till 2008 representing an average growth of only 9.2%

1.3 billion2.7 billion

20.4billion

Our ProfitsT H E P R O F I T W H I C H S E A R L E U S E D T O M A K E I N 2 0 0 7 N O W R E P R E S E N T S O N LY N I N E D AY S O F P R O F I T

2000 2020

35.17

million

2.54

billion

The profits increased sharply during the last 13years from just 64 million in 2007 to 2.54 billion in the year 2020, representing an average growth rate of 32.84%.

The reduction in net profits from 2018 is mainly due to increase in PKR-USD exchange rate (121/$-168/$) and increase in finance cost due to a sharp rise in inter-bank borrowing rates.

2007

63.54

million

Profits were unstable during 2000 to 2007 representing a much lower average growth rate of 10%.

Our Strategy

18

N E W V S . E X I S T I N G P R O D U C T P E R C E N TA G E

47% 46% 46% 43%

41% 40%

53% 54% 54%57%

59% 60%

2015 2016 2017 2018 2019 2020

54%46%

Old New

44%56%

39%61%

New products within top 10

Rapid increase in share of top

10 products:

- 2013 - 46%

- 2015 - 56%

- 2017 - 61%

Financial Information

Standalone Financials

2020 2019 2018

Revenue 16,567,219 14,537,198 12,675,110

PFO % 23.82% 22.41% 27.13%

PAT % 14.82% 18.17% 24.06%

EPS 11.56 12.44 14.35

Cash Dividend 25.00% 25.00% 50.00%

Bonus Dividend 0.00% 0.00% 15.00%

Consolidated Financials

2020 2019 2018

Revenue 20,474,842 18,062,107 16,148,468

PFO % 21.22% 18.11% 21.50%

PAT % 12.44% 12.54% 16.82%

EPS 11.77 10.55 12.65

Our FutureB L A Z I N G T O WA R D S A R A D I A N T F U T U R E

20

Will be the number 1 pharmaceutical company in Pakistan

Will have global presence in more than 50 countries

Will have the largest field force of highly trained medical representatives

Will have FDA approved manufacturing facilities

01

02

03

04

Corporate Social ResponsibilityR E S E A R C H I N T H E S E R V I C E O F M A N K I N D

• Searle is committed towards saving environment and creating a sustainable clean future. Searle plans to plant 300 thousands trees in various parks around the city of Karachi.

• Searle won the National Forum for Environment and Health CSR Awards in 2016, for those who have contributed to the society and science.

• Searle awarded a substantial grant to ICCBS for strengthening of genomic research.

• Renovated AKAR Hospital located in Karachi, as total non-profit organization working entirely on donations from the company, and restocked medicines for the hospital pharmacy.

21

Our Commitment to Society

22

R E S E A R C H I N T H E S E R V I C E O F M A N K I N D